FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1.

Silvana MouronLuis MansoEduardo CaleirasJose L Rodriguez-PeraltoOscar M RuedaCarlos CaldasRamon ColomerMiguel Quintela-FandinoMaria J Bueno

Published in: Breast cancer research : BCR (2021)

FGFR1 amplification and overexpression are associated to similar adverse prognosis in hormone-positive breast cancer. Capturing all the patients with adverse prognosis-linked FGFR1 aberrations requires assessing both features. Hormonal deprivation leads to FGFR1 overexpression, and FGFR1 overexpression and/or amplification are associated with resistance to hormonal monotherapy or in combination with palbociclib. Both resistances are reverted with triple ER, CDK4/6, and FGFR1 blockade.

Keyphrases

cell proliferation
positive breast cancer
transcription factor
nucleic acid
cell cycle
polycystic ovary syndrome
clinical trial
gene expression
emergency department
metabolic syndrome
label free
skeletal muscle
combination therapy
study protocol
metastatic breast cancer